Accumulation of l8F-FDG in the liver in hepatic steatosis

American Journal of Roentgenology

Volumn 203, Issue 3, 2014, Pages 643-648

  Keramida, Georgia ^a   Potts, Jonathan ^b   Bush, Jan ^a   Verma, Sumita ^c   Dizdarevic, Sabina ^a   Peters, Adrien M ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UK   (United Kingdom)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Blood glucose; FDG; Hepatic steatosis; LivBr; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BODY FAT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG UPTAKE; FATTY LIVER; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; IMAGE ANALYSIS; LIVER CELL; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; FDG; LIVER; METABOLISM; METHODOLOGY; PET; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

BLOOD GLUCOSE; FDG; HEPATIC STEATOSIS; LIVER; PET;

FATTY LIVER; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84907882493     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.12147     Document Type: Article

References (24)

1. El-Serag HH, Tran T, Everharl JE, Diabetes increases the risk nt chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126:460-468
2. Vernon G, Baranova A. Ybunossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatly liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; .14:274-285
3. Agopian VG, Kaldas l-'M, Hong JC, el al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 21)12: 256:624-633
4. Ekstedt M. Pranzen LE, Mathiesen UL, et al. Long-term foliow-up of patients with NA LI.1) and elevated liver enzymes. Hepatology 2006; 44:865-873
5. Atwell TD, Smith RL, Hesley GK, et al. Incidence of bleeding after 15.181 percutaneous biopsies and the role of aspirin. AJR 2010; 194:784-7X9
6. Musso G, Oambino R, Cassader M. Pagano G. Mela-analysis: natural history of non-alcoholic fatty liverdisease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43:617-649
7. Wong VW. Vergniol J. Wong GL, et al. Diagnosis of librosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hep-atology 2010; 51:454-462
8. Saadeh S. Younossi ZM. Remer EM, et al. The utility of radiologic imaging in non-alcoholic fatty liver disease. Gastroenterology2002; 123:745-750
9. SaverymuttU SH, Peters AM, Keshavar/ian A, Reavy IIJ. Lavender JP. The kinetics of 11l-indiu 111 distribution following injection of 111-indium labelled autologous granulocytes in man. Ur .1 Haematol 1985;61:675-685
10. Lin CY, Lin WY, LinCC, ShihCM. Jeng LB, Kao CH. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clin Imaging 2011; 35:437-441
11. Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. AJR 2011; 196:176-180
12. Abele JT, Fung CI. Effect of hepatic sieato.sis on liver FDG uptake measured in mean standard uptake values. Radiology 2010; 254:917-924
13. Bural GG, Torigian DA, Burke A, et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol 2010;12:233-239
14. Kamimura K, Nagamachi S. Wakamatsu H, et al. Associations between liver (18)F lluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med 2010; 24:157-161
15. Choi Y, Hawkins R A, Huang SC, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. ./ Nucl Med 1994; 35:818-823
16. Ricci C, Longo R. Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27:108-113
17. Boyce CJ, Pickhardt PJ. Kim DH, el al. Hepatic sleatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR 2010; 194:623-628
18. Zeb I, Li D, Nasir K, Katz R. Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatly liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol 2012; 19:811-818
19. Oya N, Nagata Y, Ishigaki T, et al. Evaluation of experimental liver tumors using fluorine-IX-2-fluoro-2-deoxy-d-glucose PET. J Nucl Med 1993;34:2124-2129
20. Green LA, Gamhhir SS, Sriniv asan A, et al. Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with Auorine-18-fluorodeoxyglucose.J Nucl Med 1998; 39:729-734
21. Torizuka T, Tamaki N, Inokuma T. et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med 1995; 36:1811-1817
22. Keramida G, Shur J, Uush J, Dizdarevic S, Peters AM. Contrasting relations with blood glucose level of FDG accumulation in the brain and liver: potential clinical impact. Nucl Med Commun 2013;34:376
23. de Geus-Oei LF, Visser EP, Krahbe PF, et al. Comparison of image-derived and arterial input functions for estimating the rale of glucose metabolism in therapy-monitoring '18F-FDG PET studies. J Nucl Med 2006; 47:945-949
24. Décarie PO, Lepanto L, Billiard JS, et al, Fatty liver deposition and sparing: a pictorial review. Insights Imaging 2011; 2:533-538